Pfenniger Richard C Jr's Form 4 filing
Cocrystal Pharma, Inc. (COCP) · filed Aug 23, 2021
- Accession no.
- 0001493152-21-021048
- Filed
- Aug 23, 2021
- Trade date
- Aug 20, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $41.2K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pfenniger Richard C JrCIK 0001200796 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2021 | Common Stock | PPurchaseAcquired | +40,000 | $1.03F1 | +$41,200 | 40,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $1.02 to $1.03, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in the preceding sentence.
Referenced by the price of 1 transaction in Table I.